ADVERTISEMENT

Stay up to date every week with the european biotechnology newsletter.

✕
This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
EBcom NL
This field is hidden when viewing the form
Consent

Stay up to date every week with the european biotechnology newsletter.

Log in here to read the desired article.

This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
EBcom NL
This field is hidden when viewing the form
Consent
go to the article

go back to the homepage

  • Subscription
  • Newsletter
  • Advertise
European Biotechnology Magazine
biocom_logo
  • Latest news
  • Background
  • Opinion
  • The Mag
    • Issues
    • Special
    • Corporate publications
    • Subscribe
  • Euro Biotech Guide
  • Market Place
    • Products
    • Sponsored Publications
    • Advertise
  • Associations
  • Service
    • Newsletter
    • Contact Us
    • Editorial Team
  • Events
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

ADVERTISEMENT

Meanwhile in Biotech - European Biotechnology news roundup
Meanwhile in biotech

Novartis drops Alzheimer’s program; Windward files for IPO; GSK wins hepatitis B approval

Beyond the main headlines, European biotech kept moving this week. This edition of Meanwhile in Biotech covers an Alzheimer’s program dropped from Novartis’ pipeline, a Swiss biotech’s Nasdaq ambitions, … more ➔

Photo credit: ESMO
oncology

ESMO 2026: The biggest announcements from European biopharma

The European Society for Medical Oncology (ESMO) Congress is one of the biggest events on the cancer research calendar, where clinical results can reshape treatment decisions and drug developers’ prospects. … more ➔

ADVERTISEMENT

Immatics Tübingen
clinical data

Immatics shows off its PRAME bispecific data at ESMO 2026

Germany-based cancer immunotherapy specialist Immatics presented updated clinical data for two PRAME-targeted drug candidates at the ESMO Congress 2026 in Madrid. Particularly striking is the survival … more ➔

way out sign exit
Radiopharmaceuticals

Spago Nanomedical seeks delisting to finance cancer drug development

Sweden’s Spago Nanomedical will ask shareholders on Nov. 19 to approve delisting from Nasdaq First North, arguing that its listing obstructs financing on acceptable terms for Phase 2a development of … more ➔

3D medical background with abstract virus cells
Deep Dive

Europe takes cancer science into ­immunology

Inspired by technology and ­insights gleaned from cancer research, Europe is leading the quest for a new generation of therapies in immunology and inflammation. Immunotherapy has revolutionised cancer … more ➔

European Biotechnology

1 / 4
EBM 3.2026 Autumn_cover

The autumn issue of European Biotechnology magazine asks what happens when biotech leaves Earth. Our cover story explores how microgravity could help researchers study disease, improve drug formulations … more ➔

Get a free sample copy | Abo
2 / 4

The summer issue of European Biotechnology Magazine showcases the latest developments in drug delivery and RNA technologies. This issue features a list of eight venture capital firms to watch in 2026. … more ➔

Get a free sample copy | Abo
3 / 4

The Spring 2026 issue of European Biotechnology Magazine presents a list of start-ups to watch in 2026 and explores other fascinating topics such as: Can biotechnology finally fix infertility? Can … more ➔

Get a free sample copy | Abo
4 / 4
EB425_Cover

Europe is losing much of its expertise in deep tech and life sciences to the US. To prevent another generation of innovation from being lost, Europe must close the funding gaps. more ➔

Get a free sample copy | Abo

ADVERTISEMENT

© AI
european-biotechnology-logo

NEWSLETTER


Stay up to date with the biotech industry!

Once a week, european-biotechnology.com brings you up to date on the latest developments in the biotech industry. In our free newsletter, you will find the latest news from business, research and politics, as well as lots of useful information and job vacancies.


Subscribe to our free newsletter!Subscribe here

Photo by Esma Melike Sezer via Unsplash+
ovarian cancer

Genmab’s acquisition spree starts to pay off with new ovarian and colorectal cancer data

Denmark’s Genmab has reported that its antibody-drug conjugate rinatabart sesutecan (Rina-S) reduced the risk of progression or death by 71% and the risk of death by 57%, compared with conventional chemotherapy … more ➔

Photo of Roche Tower by Basil Minhaj via Unsplash+
lung cancer

Roche bets up to $813M on Zymeworks lung cancer candidate

Swiss big pharma Roche has agreed to license ZW209, an experimental cancer immunotherapy from Vancouver-based Zymeworks, for $55 million upfront and up to $758 million more in conditional payments, plus … more ➔

ADVERTISEMENT

Sponsored Publications

1 / 3
Dr. Raphaela Schnurbus
artificial intelligence

AI in clinical research: hype vs. reality

AI can already reduce administrative work, improve decision-making and streamline parts of clinical development. But its impact is often overstated. Evidenze’s ­Raphaela Schnurbus explains where … more ➔

2 / 3
Team Invitris
artificial intelligence

Closing AI medicine’s manufacturing gap

At the IZB in Martinsried, Invitris is developing a cell-free platform to turn ­digital sequences into proteins, antibodies and phages within hours. CEO Patrick Grossmann explains why AI is shifting … more ➔

3 / 3
Professor Jacob George, Chief Medical and Scientific Officer at the MHRA presenting his keynote speech at Phacilitate Advanced Therapies Europe, 2026
Cell & Gene Therapy

Europe’s CGT advantage at risk

Industry leaders at Advanced Therapies Europe 2026 warned that Europe must tackle barriers across commercialisation, regulation, reimbursement, manufacturing and patient access to retain its global … more ➔

APPOINTMENTS

all appointments

eb.com_Jeff_Abbey_Spica_Therapeutics_CEOSpica Therapeutics
Spica Therapeutics

New CEO for the next level

The Belgian biotech company Spica Therapeutics, specialist for Macrophages biology, appointed Jeff Abbey as new Chief Executive Officer …
more ➔

EB.com_Qiagen_CEO_Jonathan_PrattQiagen
Qiagen

New CEO took over the reins

At the beginning of September, Jonathan M. Pratt succeeded Thierry Bernard as CEO of Qiagen N.V. Bernard had led the biotech pioneer …
more ➔

Samanta CimitanLonza Group
CDMO

Samanta Cimitan to (re)join Lonza from Celonic

Samanta Cimitan will join Lonza as Chief Commercial Officer (CCO), Senior Vice President and a member of the Extended Executive Committee …
more ➔

eb.com_Teresa Nunes CMO_EpilepsyGTXEpilepsyGTX
EpilepsyGTX

Clinical Development Expert has started

London-based EpilepsyGTx has appointed Dr Teresa Nunes as Chief Medical Officer (CMO) to support the continued development of the company’s …
more ➔

The Leadership Edit Thumbnail European Biotechnology
Appointments

Sensorion names CMO; Orano Med adds CSO; CRISPR Therapeutics changes CFO

Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: a hearing-loss specialist adds clinical … more ➔

ADVERTISEMENT

scrap paper
allogeneic CAR-T

Roche scraps off-the-shelf CAR-T from Poseida deal worth up to $1.5B

Switzerland’s Roche has discontinued RG6540, an experimental off-the-shelf CAR-T therapy targeting the CD19 and CD20 proteins, less than two years after agreeing to acquire its developer, Poseida Therapeutics, … more ➔

Photo by National Cancer Institute via Unsplash+
cancer immunotherapy

Menarini adds Georgiamune’s oral immunotherapy candidate to its solid-tumor portfolio for $45M upfront

Italy’s Menarini Group will pay Maryland biotech Georgiamune $45 million (€40 million) in upfront and near-term payments, in a deal worth up to $1.1 billion (€1.0 billion) plus royalties, for worldwide … more ➔

All news
newsletter_link

EVENT


Eventbild-heidelberg-2026-boehmert[21]
November 3 @ 09:00 - 13:00in Heidelberg, Germany

IP Seminar for Life Sciences & Chemistry

How can pharmaceutical, biotech and chemical companies effectively protect innovation in a rapidly evolving European patent landscape? BOEHMERT & BOEHMERT's complimentary IP Seminar in Heidelberg explores recent developments at the Unified Patent Court (UPC), the Unitary Patent system and the European Patent Office, highlighting practical strategie ... ➔

Knowbio GmbH
  • Link to LinkedIn
  • Link to Instagram
  • Contact
  • Imprint
  • Privacy policy
Scroll to top Scroll to top Scroll to top